RxDoctor Payments Data

Silpa Avula, MD

Cardiovascular Disease · San Jose, CANPI 1386675981

Payments from drug & device makers

$2,530in general payments, 2019–2025

Across 146 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$440
  • AstraZeneca$287
  • Pfizer$251
  • Boehringer Ingelheim$219
  • Merck$203
  • E.r. Squibb & Sons, L.L.C.$174
  • plus $956 from 13 others

What the payments were for

  • Food & beverage$2,19787%
  • Education$33313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,530 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$312,413
Medicare patients
269
Services billed
2,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$168,439
XareltoRivaroxaban56$82,483
EntrestoSacubitril/Valsartan48$62,666
JardianceEmpagliflozin27$36,303
FarxigaDapagliflozin Propanediol17$23,926
BrilintaTicagrelor14$11,840
Repatha SyringeEvolocumab12$6,381
Ranolazine ErRanolazine18$2,887
Metoprolol Succinate141$2,451
Atorvastatin Calcium105$1,423
Losartan Potassium110$1,243
Amiodarone Hcl17$1,229
Hydralazine Hcl92$1,037
ClopidogrelClopidogrel Bisulfate67$972
Ezetimibe21$905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$251$168,439114 claims
Johnson & JohnsonXarelto$72$82,48356 claims
NovartisEntresto$440$62,66648 claims
Boehringer IngelheimJardiance$219$36,30327 claims
AstraZenecaFarxiga, Brilinta$287$35,76631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →